Family Medicine Doctors in West Point, GA Accepting Medicare
2 Family Medicine doctors found. Showing 1 - 2
 Karan Verma, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 599 3rd Ave, West Point, GA 31833 Phone: 706-242-5081 Fax: 770-999-2887 |
Dr. James W. Parker, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1009 U.s. 29, West Point, GA 31833 Phone: 706-242-5081 Fax: 706-242-5086 |
News Archive
SI-BONE receives FDA approval for updated iFuse Implant System
SI-BONE, Inc., a medical device company that is pioneering the use of a minimally invasive surgical device to treat the sacroiliac joint announced the U.S. Food and Drug Administration approved a major modification to the existing product label.
NCPA commends U.S. Senate Finance Committee's approval of the Cantwell amendment
The National Community Pharmacists Association (NCPA) today commended the U.S. Senate Finance Committee for approving by unanimous, voice vote an amendment by U.S. Sen. Maria Cantwell (D-WA) to lower health care costs through common-sense disclosure requirements for any pharmacy benefit manager (PBM) participating in the health insurance exchanges envisioned in Chairman Max Baucus' (D-MT) America's Healthy Future Act.
Lipitor and Celebrex combined may halt prostate cancer
Researchers at Rutgers' Ernest Mario School of Pharmacy have shown that administering a combination of the widely used drugs Celebrex (celecoxib, a nonsteroidal anti-inflammatory drug) and Lipitor (atorvastatin, a cholesterol lowering drug) stops the transition of early prostate cancer to its more aggressive and potentially fatal stage.
Stomach cancer cases almost halve over the last 30 years
New Cancer Research UK figures out today reveal that stomach cancer cases in Great Britain have dropped by nearly half from around 14,000 in 1975 to 7,485 in 2006.
FDA panel votes in favour of Sunitib (Sutent) for pancreatic tumors
Pfizer Inc. announced this Tuesday that its oral multi-kinase inhibitor Sutent was determined as having a favorable benefit-risk profile by an oncology advisory committee of the FDA for the treatment of unresectable pancreatic neuroendocrine tumors. The panel voted 8-2 in favor of Sutent – generically called Sunitib malate.
› Verified 6 days ago